Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 197459, 13 pages
http://dx.doi.org/10.1155/2015/197459
Research Article

Ginseng Purified Dry Extract, BST204, Improved Cancer Chemotherapy-Related Fatigue and Toxicity in Mice

1Department of Science in Korean Medicine, Graduate School, College of Korean Medicine, Kyung Hee University, 26 Kyunghee-daero, Seoul 130-701, Republic of Korea
2Green Cross Health Science Co., Ltd., 474 Dunchon-daero, Jungwon-gu, Sungnam, Gyeonggi-do 462-806, Republic of Korea

Received 15 October 2014; Revised 21 January 2015; Accepted 24 January 2015

Academic Editor: Michał Tomczyk

Copyright © 2015 Hyun-Jung Park et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. R. Timme, M. Gruidl, and T. J. Yeatman, “Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells,” Apoptosis, vol. 18, no. 10, pp. 1163–1174, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. J. García-Foncillas and E. Díaz-Rubio, “Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome,” Clinical and Translational Oncology, vol. 12, no. 8, pp. 533–542, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Aprile, M. Ramoni, D. Keefe, and S. Sonis, “Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy,” Cancer, vol. 112, no. 2, pp. 284–292, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. P. F. Innominato, S. Giacchetti, G. A. Bjarnason et al., “Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer,” International Journal of Cancer, vol. 131, no. 11, pp. 2684–2692, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. P. F. Innominato, S. Giacchetti, T. Moreau et al., “Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer,” Cancer, vol. 119, no. 14, pp. 2564–2573, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. X. Huang, Q. Zhang, X. Kang, Y. Song, and W. Zhao, “Factors associated with cancer-related fatigue in breast cancer patients undergoing endocrine therapy in an urban setting: a cross-sectional study,” BMC Cancer, vol. 10, article 453, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. J.-U. Blohmer, J. Dunst, L. Harrison et al., “Cancer-related anemia: biological findings, clinical implications and impact on quality of life,” Oncology, vol. 68, supplement 1, pp. 12–21, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. L. J. Wood, L. M. Nail, N. A. Perrin, C. R. Elsea, A. Fischer, and B. J. Druker, “The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms,” Biological Research for Nursing, vol. 8, no. 2, pp. 157–169, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. O. J. G. Schiepers, M. C. Wichers, and M. Maes, “Cytokines and major depression,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 29, no. 2, pp. 201–217, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. M. J. Tisdale, “Mechanisms of cancer cachexia,” Physiological Reviews, vol. 89, no. 2, pp. 381–410, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. K. L. Chang, H. S. Seung, K. P. Kwang, J. H. Y. Park, S. L. Soon, and Y. C. Won, “Isoliquiritigenin inhibits tumor growth and protects the kidney and liver against chemotherapy-induced toxicity in a mouse xenograft model of colon carcinoma,” Journal of Pharmacological Sciences, vol. 106, no. 3, pp. 444–451, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Çayir, A. Karadeniz, N. Simşek et al., “Pomegranate seed extract attenuates chemotherapy-induced acute nephrotoxicity and hepatotoxicity in rats,” Journal of Medicinal Food, vol. 14, no. 10, pp. 1254–1262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. H. J. Lee, H. S. Kim, N. H. Park, H. H. Chung, J. W. Kim, and Y. S. Song, “Feasibility of oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-4) chemotherapy in heavily pretreated patients with recurrent epithelial ovarian cancer,” Cancer Research and Treatment, vol. 45, no. 1, pp. 40–47, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Molassiotis, “Managing cancer-related fatigue with acupuncture: is it all good news for patients?” Acupuncture in Medicine, vol. 31, no. 1, pp. 3–4, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Lenzi, C. Fimognari, and P. Hrelia, “Sulforaphane as a promising molecule for fighting cancer,” Cancer Treatment and Research, vol. 159, pp. 207–223, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Y. Lee, S. L. Pan, M. C. Su et al., “Furanylazaindoles: potent anticancer agents in vitro and in vivo,” Journal of Medicinal Chemistry, vol. 56, no. 20, pp. 8008–8018, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. L. G. Naso, L. Lezama, T. Rojo et al., “Biological evaluation of morin and its new oxovanadium(IV) complex as antioxidant and specific anti-cancer agents,” Chemico-Biological Interactions, vol. 206, no. 2, pp. 289–301, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. R. M. Vitale, M. Gatti, M. Carbone et al., “Minimalist hybrid ligand/receptor-based pharmacophore model for CXCR4 applied to a small-library of marine natural products led to the identification of phidianidine A as a new CXCR4 ligand exhibiting antagonist activity,” ACS Chemical Biology, vol. 8, no. 12, pp. 2762–2770, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Finnegan-John, A. Molassiotis, A. Richardson, and E. Ream, “A systematic review of complementary and alternative medicine interventions for the management of cancer-related fatigue,” Integrative Cancer Therapies, vol. 12, no. 4, pp. 276–290, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. H.-G. Kim, J.-H. Cho, S.-R. Yoo et al., “Antifatigue effects of Panax ginseng C.A. Meyer: a randomised, double-blind, placebo-controlled trial,” PLoS ONE, vol. 8, no. 4, Article ID e61271, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Wang, Y. Tian, H. Li, L. Wang, and X. Lv, “Study on quality evaluation of Panax ginseng based on effects for replenishing Qi and preventing exhaustion,” Zhongguo Zhongyao Zazhi, vol. 37, no. 13, pp. 2030–2033, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Zhou, Y. Wang, H. Tian, Q. Huang, Y. Gao, and G. Zhang, “Anti-fatigue effects of Panax notoginseng in simulation plateau-condition mice,” Pharmacognosy Magazine, vol. 8, no. 31, pp. 197–201, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. D. L. Barton, H. Liu, S. R. Dakhil et al., “Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2,” Journal of the National Cancer Institute, vol. 105, no. 16, pp. 1230–1238, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. X. F. Fei, B. X. Wang, S. Tashiro, T. J. Li, J.-S. Ma, and T. Ikejima, “Apoptotic effects of ginsenoside Rh2 on human malignant melanoma A375-S2 cells,” Acta Pharmacologica Sinica, vol. 23, no. 4, pp. 315–322, 2002. View at Google Scholar · View at Scopus
  25. H. Nakata, Y. Kikuchi, T. Tode et al., “Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells,” Japanese Journal of Cancer Research, vol. 89, no. 7, pp. 733–740, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. J. A. Park, K. Y. Lee, Y. J. Oh, K.-W. Kim, and S. K. Lee, “Activation of caspase-3 protease via a Bcl-2-insensitive pathway during the process of ginsenoside Rh2-induced apoptosis,” Cancer Letters, vol. 121, no. 1, pp. 73–81, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. D. G. Popovich and D. D. Kitts, “Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line,” Archives of Biochemistry and Biophysics, vol. 406, no. 1, pp. 1–8, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Wang, P. Yu, H. Gou et al., “Cardioprotective effects of 20(S)-ginsenoside Rh2 against doxorubicin-induced cardiotoxicity in vitro and in vivo,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 506214, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Y. K. Yue, D. Y. L. Wong, P. K. Wu et al., “The angiosuppressive effects of 20(R)- ginsenoside Rg3,” Biochemical Pharmacology, vol. 72, no. 4, pp. 437–445, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Y. Seo, J. H. Lee, N. W. Kim et al., “Effect of a fermented ginseng extract, BST204, on the expression of cyclooxygenase-2 in murine macrophages,” International Immunopharmacology, vol. 5, no. 5, pp. 929–936, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Chen, Y. Xu, Y. Zhu, and X. Li, “Anti-cancer effects of ginsenoside compound k on pediatric acute myeloid leukemia cells,” Cancer Cell International, vol. 13, no. 1, article 24, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Dong, L.-P. Bai, V. K. W. Wong et al., “The in vitro structure-related anti-cancer activity of ginsenosides and their derivatives,” Molecules, vol. 16, no. 12, pp. 10619–10630, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Hao, W. Wang, Y. Zhao, R. Zhang, and H. Wang, “Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 35, no. 3-4, pp. 109–113, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. J.-H. Kang, K.-H. Song, J.-K. Woo et al., “Ginsenoside Rp1 from Panax ginseng exhibits anti-cancer activity by down-regulation of the IGF-1R/Akt pathway in breast cancer cells,” Plant Foods for Human Nutrition, vol. 66, no. 3, pp. 298–305, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. J.-M. Kim, K.-S. Kim, Y.-W. Lee et al., “Anti-angiogenic effects of water extract of a formula consisting of pulsatilla koreana, panax ginseng and glycyrrhiza uralensis,” Zhong Xi Yi Jie He Xue Bao, vol. 9, no. 9, pp. 1005–1013, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Y. Shin, J. M. Lee, H. S. Shin et al., “Anti-cancer effect of ginsenoside F2 against glioblastoma multiforme in xenograft model in SD rats,” Journal of Ginseng Research, vol. 36, no. 1, pp. 86–92, 2012. View at Google Scholar · View at Scopus
  37. D.-F. Toh, D. N. Patel, E. C. Chan, A. Teo, S.-Y. Neo, and H.-L. Koh, “Anti-proliferative effects of raw and steamed extracts of Panax notoginseng and its ginsenoside constituents on human liver cancer cells,” Chinese Medicine, vol. 6, article no. 4, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. T. T. Mai, J. Moon, Y. Song et al., “Ginsenoside F2 induces apoptosis accompanied by protective autophagy in breast cancer stem cells,” Cancer Letters, vol. 321, no. 2, pp. 144–153, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. X.-Y. Pan, H. Guo, J. Han et al., “Ginsenoside Rg3 attenuates cell migration via inhibition of aquaporin 1 expression in PC-3M prostate cancer cells,” European Journal of Pharmacology, vol. 683, no. 1–3, pp. 27–34, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. H.-M. Park, S.-J. Kim, J.-S. Kim, and H.-S. Kang, “Reactive oxygen species mediated ginsenoside Rg3- and Rh2-induced apoptosis in hepatoma cells through mitochondrial signaling pathways,” Food and Chemical Toxicology, vol. 50, no. 8, pp. 2736–2741, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. C.-Z. Wang, G.-J. Du, Z. Zhang et al., “Ginsenoside compound K, not Rb1, possesses potential chemopreventive activities in human colorectal cancer,” International Journal of Oncology, vol. 40, no. 6, pp. 1970–1976, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Uzayisenga, P. A. Ayeka, and Y. Wang, “Anti-diabetic potential of Panax notoginseng saponins (PNS): a review,” Phytotherapy Research, vol. 28, no. 4, pp. 510–516, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Wang, Z. Zhai, N. Li et al., “Steroidal saponin of Trillium tschonoskii. Reverses multidrug resistance of hepatocellular carcinoma,” Phytomedicine, vol. 20, no. 11, pp. 985–991, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. E. C. W. Neefjes, M. J. D. L. van der Vorst, S. Blauwhoff-Buskermolen, and H. M. W. Verheul, “Aiming for a better understanding and management of cancer-related fatigue,” Oncologist, vol. 18, no. 10, pp. 1135–1143, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. F. W. Boele, L. Douw, M. de Groot et al., “The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial,” Neuro-Oncology, vol. 15, no. 10, pp. 1420–1428, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. J.-C. Chen, C.-Y. Hsiang, Y.-C. Lin, and T.-Y. Ho, “Deer antler extract improves fatigue effect through altering the expression of genes related to muscle strength in skeletal muscle of mice,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 540580, 10 pages, 2014. View at Publisher · View at Google Scholar
  47. J. L. Ryan, J. K. Carroll, E. P. Ryan, K. M. Mustian, K. Fiscella, and G. R. Morrow, “Mechanisms of cancer-related fatigue,” Oncologist, vol. 12, no. 1, pp. 22–34, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. A. J. Richardson, J. M. Laurence, and V. W. T. Lam, “Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review,” Journal of Vascular and Interventional Radiology, vol. 24, no. 8, pp. 1209–1217, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. T.-P. Huynh, P. Pieta, F. D'Souza, and W. Kutner, “Molecularly imprinted polymer for recognition of 5-fluorouracil by RNA-type nucleobase pairing,” Analytical Chemistry, vol. 85, no. 17, pp. 8304–8312, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. T.-J. Li, C.-C. Huang, P.-W. Ruan et al., “In vivo anti-cancer efficacy of magnetite nanocrystal—based system using locoregional hyperthermia combined with 5-fluorouracil chemotherapy,” Biomaterials, vol. 34, no. 32, pp. 7873–7883, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. E. Jastrzebska, S. Flis, A. Rakowska et al., “A microfluidic system to study the cytotoxic effect of drugs: the combined effect of celecoxib and 5-fluorouracil on normal and cancer cells,” Microchimica Acta, vol. 180, no. 9-10, pp. 895–901, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Reers, A. C. Pfannerstill, D. Rades et al., “Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer,” Anticancer Research, vol. 33, no. 6, pp. 2481–2489, 2013. View at Google Scholar
  53. H. L. Wong, R. Bendayan, A. M. Rauth, Y. Li, and X. Y. Wu, “Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles,” Advanced Drug Delivery Reviews, vol. 59, no. 6, pp. 491–504, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Boulin, S. Guiu, B. Chauffert et al., “Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma,” Anti-Cancer Drugs, vol. 22, no. 8, pp. 741–748, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. Y.-F. Ho, W.-C. Lu, R. R.-L. Chen, A.-L. Cheng, and K.-H. Yeh, “Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers,” Anti-Cancer Drugs, vol. 22, no. 3, pp. 290–298, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. M. A. Ray, R. A. Trammell, S. Verhulst, S. Ran, and L. A. Toth, “Development of a mouse model for assessing fatigue during chemotherapy,” Comparative Medicine, vol. 61, no. 2, pp. 119–130, 2011. View at Google Scholar · View at Scopus
  57. J. A. Zombeck, E. G. Fey, G. D. Lyng, and S. T. Sonis, “A clinically translatable mouse model for chemotherapy-related fatigue,” Comparative Medicine, vol. 63, no. 6, pp. 491–497, 2013. View at Google Scholar · View at Scopus
  58. A. Cozzoli, R. F. Capogrosso, V. T. Sblendorio et al., “GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy,” Pharmacological Research, vol. 72, pp. 9–24, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. T.-J. Li, C.-C. Huang, P.-W. Ruan et al., “In vivo anti-cancer efficacy of magnetite nanocrystal—based system using locoregional hyperthermia combined with 5-fluorouracil chemotherapy,” Biomaterials, vol. 34, no. 32, pp. 7873–7883, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Bar-Yehuda, L. Madi, D. Silberman, S. Gery, M. Shkapenuk, and P. Fishman, “CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model,” Neoplasia, vol. 7, no. 1, pp. 85–90, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. C. D. Britten, S. G. Hilsenbeck, S. G. Eckhardt et al., “Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model,” Cancer Research, vol. 59, no. 5, pp. 1049–1053, 1999. View at Google Scholar · View at Scopus
  62. K. Riviere, H. M. Kieler-Ferguson, K. Jerger, and F. C. Szoka Jr., “Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan,” Journal of Controlled Release, vol. 153, no. 3, pp. 288–296, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. C.-C. Huang, T.-J. Lin, Y.-F. Lu, C.-C. Chen, C.-Y. Huang, and W.-T. Lin, “Protective effects of L-arginine supplementation against exhaustive exercise-induced oxidative stress in young rat tissues,” Chinese Journal of Physiology, vol. 52, no. 5, pp. 306–315, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. W. D. Bowers Jr., R. W. Hubbard, I. Leav et al., “Alterations of rat liver subsequent to heat overload,” Archives of Pathology & Laboratory Medicine, vol. 102, no. 3, pp. 154–157, 1978. View at Google Scholar · View at Scopus
  65. C.-Z. Hong and I.-N. Lien, “Metabolic effects of exhaustive training of athletes,” Archives of Physical Medicine and Rehabilitation, vol. 65, no. 7, pp. 362–365, 1984. View at Google Scholar · View at Scopus
  66. J. Zeng, H. Wang, X.-M. Jia, C.-Y. Li, and F. Li, “Effect of ginsenoside Rg3 on hepatic fibrosis in murine schistosomiasis japonica,” Chinese Journal of Parasitology & Parasitic Diseases, vol. 29, no. 2, pp. 107–110, 2011. View at Google Scholar · View at Scopus
  67. Y. Yu, C. Zhang, L. Liu, and X. Li, “Hepatic arterial administration of ginsenoside Rg3 and transcatheter arterial embolization for the treatment of VX2 liver carcinomas,” Experimental and Therapeutic Medicine, vol. 5, no. 3, pp. 761–766, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. W. Tang, Y. Zhang, J. Gao, X. Ding, and S. Gao, “The anti-fatigue effect of 20(R)-ginsenoside Rg3 in mice by intranasally administration,” Biological and Pharmaceutical Bulletin, vol. 31, no. 11, pp. 2024–2027, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Lee, M.-S. Lee, C.-T. Kim, I.-H. Kim, and Y. Kim, “Ginsenoside RG3 reduces lipid accumulation with AMP-activated protein kinase (AMPK) activation in HepG2 cells,” International Journal of Molecular Sciences, vol. 13, no. 5, pp. 5729–5739, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. K. S. Kang, H. Y. Kim, N. Yamabe, J. H. Park, and T. Yokozawa, “Preventive effect of 20(S)-ginsenoside Rg3 against lipopolysaccharide-induced hepatic and renal injury in rats,” Free Radical Research, vol. 41, no. 10, pp. 1181–1188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. S. I. Gum and M. K. Cho, “Korean red ginseng extract prevents APAP-induced hepatotoxicity through metabolic enzyme regulation: the role of ginsenoside Rg3, a protopanaxadiol,” Liver International, vol. 33, no. 7, pp. 1071–1084, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. R. S. Z. Lodhi, K. Nakabayashi, K. Suzuki et al., “Relaxin has anti-apoptotic effects on human trophoblast-derived HTR-8/SV neo cells,” Gynecological Endocrinology, vol. 29, no. 12, pp. 1051–1054, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. X.-P. Tang, G.-D. Tang, C.-Y. Fang, Z.-H. Liang, and L.-Y. Zhang, “Effects of ginsenoside Rh2 on growth and migration of pancreatic cancer cells,” World Journal of Gastroenterology, vol. 19, no. 10, pp. 1582–1592, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. M. C. Mocellin, J. D. A. Pastore e Silva, C. D. Q. Camargo et al., “Fish oil decreases C-reactive protein/albumin ratio improving nutritional prognosis and plasma fatty acid profile in colorectal cancer patients,” Lipids, vol. 48, no. 9, pp. 879–888, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. R. Dantzer, J. C. O'Connor, G. G. Freund, R. W. Johnson, and K. W. Kelley, “From inflammation to sickness and depression: when the immune system subjugates the brain,” Nature Reviews Neuroscience, vol. 9, no. 1, pp. 46–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Munzer, U. Sack, R. Mergl et al., “Impact of antidepressants on cytokine production of depressed patients in vitro,” Toxins, vol. 5, no. 11, pp. 2227–2240, 2013. View at Publisher · View at Google Scholar
  77. R. Villanueva, “Neurobiology of major depressive disorder,” Neural Plasticity, vol. 2013, Article ID 873278, 7 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. P. J. McGuire, T. N. Tarasenko, T. Wang et al., “Acute metabolic decompensation due to influenza in a mouse model of ornithine transcarbamylase deficiency,” Disease Models and Mechanisms, vol. 7, no. 2, pp. 205–213, 2014. View at Publisher · View at Google Scholar · View at Scopus
  79. Y. Zhang, L. Liu, Y.-L. Peng et al., “Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors,” CNS Neuroscience and Therapeutics, vol. 20, no. 2, pp. 119–124, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. J. E. Bower, “Cancer-related fatigue: links with inflammation in cancer patients and survivors,” Brain, Behavior, and Immunity, vol. 21, no. 7, pp. 863–871, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. J. E. Bower and D. M. Lamkin, “Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications,” Brain, Behavior, and Immunity, vol. 30, supplement, pp. S48–S57, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Kamath, “Cancer-related fatigue, inflammation and thyrotropin-releasing hormone,” Current Aging Science, vol. 5, no. 3, pp. 195–202, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. J. E. Bower, P. A. Ganz, N. Aziz, and J. L. Fahey, “Fatigue and proinflammatory cytokine activity in breast cancer survivors,” Psychosomatic Medicine, vol. 64, no. 4, pp. 604–611, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Fraczek, D. Sanocka, M. Kamieniczna, and M. Kurpisz, “Proinflammatory cytokines as an intermediate factor enhancing lipid sperm membrane peroxidation in in vitro conditions,” Journal of Andrology, vol. 29, no. 1, pp. 85–92, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. L. A. Michaels, K. Ohene-Frempong, H. Zhao, and S. D. Douglas, “Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis,” Blood, vol. 92, no. 9, pp. 3148–3151, 1998. View at Google Scholar · View at Scopus
  86. S. Kuvibidila, R. Gardner, D. Ode, L. Yu, G. Lane, and R. P. Warrier, “Tumor necrosis factor alpha in children with sickle cell disease in stable condition,” Journal of the National Medical Association, vol. 89, no. 9, pp. 609–615, 1997. View at Google Scholar · View at Scopus
  87. S. C. Taylor, S. J. Shacks, and Z. Qu, “In vivo production of type 1 cytokines in healthy sickle cell disease patients,” Journal of the National Medical Association, vol. 91, no. 11, pp. 619–624, 1999. View at Google Scholar · View at Scopus
  88. R. B. Francis Jr. and L. J. Haywood, “Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease,” Journal of the National Medical Association, vol. 84, no. 7, pp. 611–615, 1992. View at Google Scholar · View at Scopus
  89. I. Malave, Y. Perdomo, E. Escalona et al., “Levels of tumor necrosis factor alpha/cachectin (TNF alpha) in sera from patients with sickle cell disease,” Acta Haematologica, vol. 90, no. 4, pp. 172–176, 1993. View at Publisher · View at Google Scholar · View at Scopus
  90. M.-Y. Rhee, B. Cho, K.-I. Kim et al., “Blood pressure lowering effect of korea ginseng derived ginseol K-g1,” The American Journal of Chinese Medicine, vol. 42, no. 3, pp. 605–618, 2014. View at Publisher · View at Google Scholar · View at Scopus
  91. K. Murata, F. Takeshita, K. Samukawa, T. Tani, and H. Matsuda, “Effects of ginseng rhizome and ginsenoside RO on testosterone 5alpha-reductase and hair re-growth in testosterone-treated mice,” Phytotherapy Research, vol. 26, no. 1, pp. 48–53, 2012. View at Publisher · View at Google Scholar · View at Scopus
  92. T. Tao, F. Chen, L. Bo et al., “Ginsenoside Rg1 protects mouse liver against ischemia-reperfusion injury through anti-inflammatory and anti-apoptosis properties,” Journal of Surgical Research, vol. 191, no. 1, pp. 231–238, 2014. View at Publisher · View at Google Scholar · View at Scopus
  93. S.-J. Tan, N. Li, F. Zhou et al., “Ginsenoside Rb1 improves energy metabolism in the skeletal muscle of an animal model of postoperative fatigue syndrome,” Journal of Surgical Research, vol. 191, no. 2, pp. 344–349, 2014. View at Publisher · View at Google Scholar · View at Scopus
  94. M.-K. Choo, E.-K. Park, M. J. Han, and D.-H. Kim, “Antiallergic activity of ginseng and its ginsenosides,” Planta Medica, vol. 69, no. 6, pp. 518–522, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. E.-K. Park, M.-K. Choo, E.-J. Kim, M. J. Han, and D.-H. Kim, “Antiallergic activity of ginsenoside Rh2,” Biological and Pharmaceutical Bulletin, vol. 26, no. 11, pp. 1581–1584, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. J.-Y. Wu, B. H. Gardner, C. I. Murphy et al., “Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine,” The Journal of Immunology, vol. 148, no. 5, pp. 1519–1525, 1992. View at Google Scholar · View at Scopus
  97. J. W. Liu, J. X. Chen, L. H. Yu et al., “Inhibitory effect of ginsenoside-Rg3 on lung metastasis of mouse melanoma transfected with ribonuclease inhibitor,” Zhonghua Zhong Liu Za Zhi, vol. 26, no. 12, pp. 722–725, 2004. View at Google Scholar · View at Scopus
  98. M. Mochizuki, K. Matsuzawa, K. Sato et al., “Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside- Rb2, 20(R)- and 20(S)-ginsenoside-Rg3, of Red ginseng,” Biological and Pharmaceutical Bulletin, vol. 18, no. 9, pp. 1197–1202, 1995. View at Publisher · View at Google Scholar · View at Scopus
  99. K. Shinkai, H. Akedo, M. Mukai et al., “Inhibition of in vitro tumor cell invasion by ginsenoside Rg3,” Japanese Journal of Cancer Research, vol. 87, no. 4, pp. 357–362, 1996. View at Publisher · View at Google Scholar · View at Scopus
  100. H. Tao, M. Yao, S. Zou, D. Zhao, and H. Qiu, “Effect of angiogenesis inhibitor Rg3 on the growth and metastasis of gastric cancer in SCID mice,” Chinese Journal of Surgery, vol. 40, no. 8, pp. 606–608, 2002. View at Google Scholar · View at Scopus
  101. T.-M. Xu, M.-H. Cui, Y. Xin et al., “Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis,” Chinese Medical Journal, vol. 121, no. 15, pp. 1394–1397, 2008. View at Google Scholar · View at Scopus
  102. X. Wei, F. Su, X. Su, T. Hu, and S. Hu, “Stereospecific antioxidant effects of ginsenoside Rg3 on oxidative stress induced by cyclophosphamide in mice,” Fitoterapia, vol. 83, no. 4, pp. 636–642, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. X. Wei, J. Chen, F. Su, X. Su, T. Hu, and S. Hu, “Stereospecificity of ginsenoside Rg3 in promotion of the immune response to ovalbumin in mice,” International Immunology, vol. 24, no. 7, pp. 465–471, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. J. Sun, S. Hu, and X. Song, “Adjuvant effects of protopanaxadiol and protopanaxatriol saponins from ginseng roots on the immune responses to ovalbumin in mice,” Vaccine, vol. 25, no. 6, pp. 1114–1120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. J. S. Park, E. M. Park, D. H. Kim et al., “Anti-inflammatory mechanism of ginseng saponins in activated microglia,” Journal of Neuroimmunology, vol. 209, no. 1-2, pp. 40–49, 2009. View at Publisher · View at Google Scholar · View at Scopus
  106. B. D. Fu, W. Y. Bi, C. L. He et al., “Sulfated derivatives of 20(S)-ginsenoside Rh2 and their inhibitory effects on LPS-induced inflammatory cytokines and mediators,” Fitoterapia, vol. 84, no. 1, pp. 303–307, 2013. View at Publisher · View at Google Scholar · View at Scopus
  107. K.-S. Chung, S.-H. Cho, J.-S. Shin et al., “Ginsenoside Rh2 induces cell cycle arrest and differentiation in human leukemia cells by upregulating TGF-β expression,” Carcinogenesis, vol. 34, no. 2, pp. 331–340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. W.-Y. Bi, B.-D. Fu, H.-Q. Shen et al., “Sulfated derivative of 20(S)-ginsenoside Rh2 inhibits inflammatory cytokines through MAPKs and NF-kappa B pathways in LPS-Induced RAW264.7 macrophages,” Inflammation, vol. 35, no. 5, pp. 1659–1668, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. V. Mock, A. Atkinson, A. Barsevick et al., “NCCN practice guidelines for cancer-related fatigue,” Oncology (Williston Park), vol. 14, no. 11, pp. 151–161, 2000. View at Google Scholar · View at Scopus
  110. E. A. Barnes and E. Bruera, “Fatigue in patients with advanced cancer: a review,” International Journal of Gynecological Cancer, vol. 12, no. 5, pp. 424–428, 2002. View at Publisher · View at Google Scholar · View at Scopus
  111. T. S. Armstrong, S. G. Cron, E. V. Bolanos, M. R. Gilbert, and D. H. Kang, “Risk factors for fatigue severity in primary brain tumor patients,” Cancer, vol. 116, no. 11, pp. 2707–2715, 2010. View at Publisher · View at Google Scholar · View at Scopus